On Wednesday, H.C. Wainwright maintained a positive outlook on OKYO Pharma Ltd. (NASDAQ: OKYO), reiterating a Buy rating and a $7.00 price target for the company's stock.
This affirmation comes on the heels of an announcement by Clearside Biomedical (NASDAQ:CLSD) that the Phase 2b ODYSSEY trial for its wet Age-related Macular Degeneration (AMD (NASDAQ:AMD)) treatment, CLS-AX, has reached a significant milestone.
The final participant visit for the ODYSSEY trial was completed, as announced by Clearside Biomedical on August 27, 2024. The trial's study database is currently undergoing a cleaning and verification process. Topline data from the trial is anticipated to be reported during the week of October 7, 2024, which is a key event for stakeholders.
The Safety Review Committee previously examined the masked safety data in July and reported no significant drug-related Serious Adverse Events (SAEs), including no instances of endophthalmitis or retinal vasculitis. These findings are crucial as they suggest a favorable safety profile for CLS-AX.
Both arms of the study have concluded six months of treatment, with the CLS-AX arm receiving re-dosing as per the study's protocol. The data gathered from this re-dosing schedule is expected to inform the design of a future Phase 3 pivotal program, marking an essential step in the drug's development pathway.
Investors and industry watchers are looking forward to the upcoming data release, which could provide further insights into the drug's efficacy and safety. The continued endorsement by H.C. Wainwright signals confidence in OKYO Pharma's prospects and the potential of its associated treatments in the pipeline.
In other recent news, OKYO Pharma has secured a key U.S. patent for its dry eye disease (DED) treatment, OK-101, bolstering its intellectual property portfolio. The firm is also preparing for a Phase 2 trial of OK-101 to treat neuropathic corneal pain (NCP), a condition currently lacking an FDA-approved therapy. These developments are part of OKYO Pharma's ongoing efforts to address unmet medical needs in ocular diseases.
Furthermore, the company's Executive Chairman, Gabriele Cerrone, has increased his stake in OKYO Pharma, demonstrating confidence in the company's direction. This move comes alongside a maintained Buy rating for OKYO Pharma from analysts at H.C. Wainwright, indicating the potential of OK-101 to become the first FDA-approved therapy for NCP.
Additionally, OKYO Pharma's CEO, Dr. Gary S. Jacob, is scheduled to appear on Bloomberg TV, providing insights into the company's business strategy and ongoing projects. The company has also announced its participation in the upcoming H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. These initiatives underscore OKYO Pharma's commitment to advancing its pipeline of therapeutics and addressing unmet medical needs in ophthalmology.
InvestingPro Insights
In light of H.C. Wainwright's maintained Buy rating and $7.00 price target for OKYO Pharma Ltd. (NASDAQ: OKYO), InvestingPro data and tips provide additional context for investors considering the company's stock. As of the last twelve months ending in Q4 2024, OKYO Pharma has a market capitalization of $36.88 million and a negative P/E ratio, indicating that the company is not currently profitable. Specifically, the P/E ratio stands at -1.92, adjusted to -2.19 for the same period. This aligns with the InvestingPro Tip that OKYO has not been profitable over the last twelve months.
Additionally, the company's stock has experienced a significant decline in price total return, with a -61.06% change over the past year. This could be reflective of the InvestingPro Tip that the stock price often moves in the opposite direction of the market. Despite these challenges, OKYO's stock price saw a 5.83% increase over the past week, suggesting some recent positive momentum.
Investors should also be aware that OKYO does not pay a dividend to shareholders, which may influence the investment strategy for those seeking regular income. For a deeper dive into OKYO Pharma's financials and for access to more InvestingPro Tips, interested parties can explore the additional 16 tips available on the InvestingPro platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.